[
  {
    "problem_id": "1",
    "premise": "Outcome Measurement: Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab. Response is defined as corrected serum calcium (CSC) \u2264 11.5 mg/dL within 10 days after the first dose of denosumab. For all CSC values, if albumin was \u2264 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium [mg/dL] + (0.8 \u00d7 (4 - serum albumin [g/dL])). Time frame: 10 days. Results: Overall Number of Participants Analyzed: 33. Unit of Measure: percentage of participants: 63.6% (95% CI: 45.1 to 79.6).",
    "statement": "Denosumab corrects serum calcium levels in participants",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T and Y): T = Denosumab, Y = corrected serum calcium levels (CSC \u2264 11.5 mg/dL).\n2. Premise shows 63.6% of participants achieved CSC \u2264 11.5 mg/dL post-treatment. However, there is no control group or baseline measurement reported (e.g., CSC levels before treatment or in untreated patients).\n3. The statement makes a causal claim ('corrects'), but the premise only shows post-treatment outcomes without comparison to natural course/placebo. \n4. While the treatment is temporally followed by outcome, causation cannot be established without evidence that CSC levels wouldn't have normalized without intervention.\n5. No mechanism data or confounder control mentioned. The evidence shows association but not causation due to lack of comparator.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T and Y): T = Denosumab, Y = corrected serum calcium levels (CSC \u2264 11.5 mg/dL).\n2. Premise shows 63.6% of participants achieved CSC \u2264 11.5 mg/dL post-treatment. However, there is no control group or baseline measurement reported (e.g., CSC levels before treatment or in untreated patients).\n3. The statement makes a causal claim ('corrects'), but the premise only shows post-treatment outcomes without comparison to natural course/placebo. \n4. While the treatment is temporally followed by outcome, causation cannot be established without evidence that CSC levels wouldn't have normalized without intervention.\n5. No mechanism data or confounder control mentioned. The evidence shows association but not causation due to lack of comparator.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "2",
    "premise": "Adverse Events 1: Total: 4/11 (36.36%). Blood bilirubin increased 1/11 (9.09%), Febrile neutropenia 1/11 (9.09%), Ejection fraction decreased 1/11 (9.09%), Supraventricular and nodal arrhythmia (Sinus tachycardia) 1/11 (9.09%), Sepsis 1/11 (9.09%), Lymphocyte count decreased 1/11 (9.09%), Neutrophil count decreased 1/11 (9.09%), Neutrophils/granulocytes (ANC/AGC) 1/11 (9.09%).",
    "statement": "The treatment was effective, although carries associated risks to hematologic health, heart rhythm, and immune response.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T (treatment) and Y (adverse effects on hematologic health, heart rhythm, and immune response).\n2. Premise reports multiple adverse events including lymphocyte/neutrophil count decreases (hematologic), sinus tachycardia (heart rhythm), and sepsis (immune response).\n3. However, the premise only reports absolute rates in the treatment group (4/11) without control group data or baseline comparison.\n4. Core principle: Causal claims require comparator data to establish treatment effect vs. natural occurrence.\n5. While the described adverse events align with the statement's risk areas, the absence of control group rates or statistical comparison prevents causal attribution.\n6. The premise shows correlation but lacks evidence of causation due to missing comparator.\n7. Directionality cannot be confirmed as increased risk compared to baseline/control isn't demonstrated.\n8. Strength of evidence is insufficient for causal claim despite domain alignment.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T (treatment) and Y (adverse effects on hematologic health, heart rhythm, and immune response).\n2. Premise reports multiple adverse events including lymphocyte/neutrophil count decreases (hematologic), sinus tachycardia (heart rhythm), and sepsis (immune response).\n3. However, the premise only reports absolute rates in the treatment group (4/11) without control group data or baseline comparison.\n4. Core principle: Causal claims require comparator data to establish treatment effect vs. natural occurrence.\n5. While the described adverse events align with the statement's risk areas, the absence of control group rates or statistical comparison prevents causal attribution.\n6. The premise shows correlation but lacks evidence of causation due to missing comparator.\n7. Directionality cannot be confirmed as increased risk compared to baseline/control isn't demonstrated.\n8. Strength of evidence is insufficient for causal claim despite domain alignment.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "3",
    "premise": "Outcome Measurement: Proportion of Patients With Blood Pressure <140/90 mmHg at Week 12. Blood pressure was measured at baseline and at week 12 after starting amlodipine. Time Frame: 12 weeks. Results: 70.2% of 47 patients had blood pressure <140/90 mmHg at week 12. 95% CI: 56.4 to 81.8.",
    "statement": "Amlodipine lowers blood pressure in patients.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. T (treatment) is amlodipine, Y (outcome) is lowering blood pressure. The premise reports 70.2% of patients achieved BP <140/90 mmHg at week 12 but provides no baseline BP values or control group comparison. 2. Causal claims require evidence of change from baseline (pre-post comparison) or difference vs control group. 3. The premise only shows post-intervention values without reference points, making it impossible to determine if amlodipine caused the BP reduction. 4. While the outcome is favorable, the absence of baseline measurements or comparator group prevents causal attribution. 5. This constitutes insufficient evidence for causation (neutral) rather than direct contradiction.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. T (treatment) is amlodipine, Y (outcome) is lowering blood pressure. The premise reports 70.2% of patients achieved BP <140/90 mmHg at week 12 but provides no baseline BP values or control group comparison. 2. Causal claims require evidence of change from baseline (pre-post comparison) or difference vs control group. 3. The premise only shows post-intervention values without reference points, making it impossible to determine if amlodipine caused the BP reduction. 4. While the outcome is favorable, the absence of baseline measurements or comparator group prevents causal attribution. 5. This constitutes insufficient evidence for causation (neutral) rather than direct contradiction.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "4",
    "premise": "Outcome Measurement: Percentage of Patients With HbA1c <7% After 24 Weeks of Treatment With Sitagliptin. HbA1c levels were assessed at baseline and at the end of 24 weeks. Time Frame: 24 weeks. Results: 58.3% of 60 patients achieved HbA1c <7%. 95% CI: 44.9 to 70.9.",
    "statement": "Sitagliptin causes a reduction in HbA1c levels in patients.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T (Sitagliptin) and Y (HbA1c levels). The statement makes a causal claim (T causes reduction in Y).\n2. The premise reports 58.3% of patients achieved HbA1c <7% post-treatment but does NOT provide baseline HbA1c values or a control group comparison.\n3. Without baseline measurements, we cannot determine if HbA1c levels were reduced from higher values (required for causal reduction).\n4. The confidence interval only describes precision of the final proportion, not change from baseline.\n5. No comparator group exists to rule out alternative explanations (e.g., natural progression).\n6. While achieving HbA1c <7% implies good control, this endpoint alone cannot demonstrate causal reduction without baseline data or control group comparison.\n7. The premise provides correlational evidence (treatment + outcome co-occurrence) but lacks temporal comparison required for causal claims.",
        "pred": "neutral",
        "fact_verification": "incorrect",
        "reasoning_verification": "correct",
        "overall_verification": false
      },
      {
        "reasoning": "1. Identify T (Sitagliptin) and Y (HbA1c levels). The statement claims T causes reduction in Y.\n2. Correction: The premise DOES include baseline HbA1c assessments (temporal comparison exists), but crucially lacks numerical baseline values (e.g., % of patients with HbA1c <7% at baseline) to quantify any reduction.\n3. Without baseline HbA1c percentages, we cannot confirm Y was reduced from higher values (required for causal reduction claim).\n4. No control group comparison exists to isolate Sitagliptin's effect from other factors.\n5. Achieving HbA1c <7% post-treatment (58.3%) only shows endpoint attainment, not causal reduction (could reflect maintenance of pre-existing levels).\n6. Confidence interval describes endpoint precision, not causal effect magnitude.\n7. Causal principles unmet: No comparator to establish effect direction (increase/decrease vs baseline/control), insufficient temporal quantification (baseline exists but lacks data).",
        "pred": "neutral"
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T (Sitagliptin) and Y (HbA1c levels). The statement claims T causes reduction in Y.\n2. Correction: The premise DOES include baseline HbA1c assessments (temporal comparison exists), but crucially lacks numerical baseline values (e.g., % of patients with HbA1c <7% at baseline) to quantify any reduction.\n3. Without baseline HbA1c percentages, we cannot confirm Y was reduced from higher values (required for causal reduction claim).\n4. No control group comparison exists to isolate Sitagliptin's effect from other factors.\n5. Achieving HbA1c <7% post-treatment (58.3%) only shows endpoint attainment, not causal reduction (could reflect maintenance of pre-existing levels).\n6. Confidence interval describes endpoint precision, not causal effect magnitude.\n7. Causal principles unmet: No comparator to establish effect direction (increase/decrease vs baseline/control), insufficient temporal quantification (baseline exists but lacks data).",
      "pred": "neutral"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "5",
    "premise": "Adverse Events Summary: Total: 5/15 (33.33%). Elevated liver enzymes 2/15 (13.33%), Nausea 1/15 (6.67%), Thrombocytopenia 1/15 (6.67%), Bradycardia 1/15 (6.67%), Hypokalemia 1/15 (6.67%).",
    "statement": "The treatment proved effective, though some patients experienced issues with liver function, heart rate, and electrolyte balance.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "The statement claims the treatment was effective (positive causal effect) but caused specific adverse events. The premise only reports adverse event rates (33.33% total) including liver enzymes (13.33%), bradycardia (6.67%), and hypokalemia (6.67%). However, the premise contains no data about treatment efficacy outcomes (e.g., disease improvement, survival rates) or any comparator group showing treatment effect. Causal claims about effectiveness require evidence comparing outcomes between treatment and control groups, which is absent here. While the premise confirms the adverse events mentioned in the statement, the claim about effectiveness lacks supporting evidence. Since there is no efficacy data to evaluate the causal claim 'proved effective', this aspect remains unproven.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "The statement claims the treatment was effective (positive causal effect) but caused specific adverse events. The premise only reports adverse event rates (33.33% total) including liver enzymes (13.33%), bradycardia (6.67%), and hypokalemia (6.67%). However, the premise contains no data about treatment efficacy outcomes (e.g., disease improvement, survival rates) or any comparator group showing treatment effect. Causal claims about effectiveness require evidence comparing outcomes between treatment and control groups, which is absent here. While the premise confirms the adverse events mentioned in the statement, the claim about effectiveness lacks supporting evidence. Since there is no efficacy data to evaluate the causal claim 'proved effective', this aspect remains unproven.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "6",
    "premise": "Adverse Events Summary: 6/20 (30.00%). Headache 3/20 (15.00%), Fatigue 2/20 (10.00%), Rash 1/20 (5.00%). All adverse events were Grade 1 or 2.",
    "statement": "The drug was effective and safe, but commonly caused mild side effects such as headache and fatigue.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Causal claim identification: The statement makes a causal claim that the drug 'commonly caused mild side effects' (T=drug, Y=side effects).\n2. Control/baseline evaluation: The premise only reports absolute adverse event rates (30% total, 15% headache) without comparison to a control group or baseline rates in untreated populations.\n3. Causation assessment: While the premise documents co-occurrence of side effects with drug administration, it lacks essential causal evidence components:\n   - No comparator group showing lower rates of these symptoms\n   - No temporal evidence establishing symptoms followed drug administration\n   - No exclusion of alternative causes\n4. Safety/efficacy claims: The premise contains no effectiveness data and safety claims require risk-benefit analysis not provided.\n5. Directionality: The reported side effect rates (15% total headache) could be considered 'common' in some contexts, but without control group data showing these rates exceed background levels, causation cannot be confirmed per core principles.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Causal claim identification: The statement makes a causal claim that the drug 'commonly caused mild side effects' (T=drug, Y=side effects).\n2. Control/baseline evaluation: The premise only reports absolute adverse event rates (30% total, 15% headache) without comparison to a control group or baseline rates in untreated populations.\n3. Causation assessment: While the premise documents co-occurrence of side effects with drug administration, it lacks essential causal evidence components:\n   - No comparator group showing lower rates of these symptoms\n   - No temporal evidence establishing symptoms followed drug administration\n   - No exclusion of alternative causes\n4. Safety/efficacy claims: The premise contains no effectiveness data and safety claims require risk-benefit analysis not provided.\n5. Directionality: The reported side effect rates (15% total headache) could be considered 'common' in some contexts, but without control group data showing these rates exceed background levels, causation cannot be confirmed per core principles.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "7",
    "premise": "Treatment-Emergent Adverse Events: 7/18 (38.89%). Anemia 2/18 (11.11%), Hypertension 2/18 (11.11%), Dizziness 1/18 (5.56%), Insomnia 1/18 (5.56%), Constipation 1/18 (5.56%).",
    "statement": "While the treatment was beneficial, patients frequently experienced elevated blood pressure and sleep disturbances.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T (treatment) and Y (adverse events: hypertension and sleep disturbances).\n2. Premise reports 2/18 (11.11%) hypertension and 1/18 (5.56%) insomnia in the treatment group.\n3. No control group or baseline data provided to compare adverse event rates.\n4. Causal claims require evidence of increased incidence relative to a comparator (core principle #2).\n5. While the events occurred, frequency interpretation ('frequently') and causal attribution depend on missing baseline/control data.\n6. Without comparison, we cannot confirm if rates are elevated beyond expected levels (neutral per decision procedure).",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T (treatment) and Y (adverse events: hypertension and sleep disturbances).\n2. Premise reports 2/18 (11.11%) hypertension and 1/18 (5.56%) insomnia in the treatment group.\n3. No control group or baseline data provided to compare adverse event rates.\n4. Causal claims require evidence of increased incidence relative to a comparator (core principle #2).\n5. While the events occurred, frequency interpretation ('frequently') and causal attribution depend on missing baseline/control data.\n6. Without comparison, we cannot confirm if rates are elevated beyond expected levels (neutral per decision procedure).",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "8",
    "premise": "Outcome: Proportion of patients achieving LDL cholesterol <100 mg/dL after 8 weeks of atorvastatin therapy. Results: 52.4% (11/21) of patients achieved the target. Time frame: 8 weeks.",
    "statement": "Atorvastatin effectively lowers LDL cholesterol in most patients.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T (atorvastatin) and Y (LDL cholesterol <100 mg/dL). The statement makes a causal claim about T's effectiveness in lowering LDL.\n2. The premise reports 52.4% of patients achieved the target LDL level after treatment but lacks: \n   - Baseline LDL measurements before treatment\n   - Control group data (e.g., placebo comparison)\n3. Without baseline or comparator data, we cannot determine if the observed effect was caused by T rather than other factors or regression to the mean.\n4. While 52.4% might suggest effectiveness, causal attribution requires evidence of comparative improvement from baseline or vs control, which is absent.\n   the premise.\n5. The premise only shows post-treatment outcomes, not causal evidence of LDL reduction.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T (atorvastatin) and Y (LDL cholesterol <100 mg/dL). The statement makes a causal claim about T's effectiveness in lowering LDL.\n2. The premise reports 52.4% of patients achieved the target LDL level after treatment but lacks: \n   - Baseline LDL measurements before treatment\n   - Control group data (e.g., placebo comparison)\n3. Without baseline or comparator data, we cannot determine if the observed effect was caused by T rather than other factors or regression to the mean.\n4. While 52.4% might suggest effectiveness, causal attribution requires evidence of comparative improvement from baseline or vs control, which is absent.\n   the premise.\n5. The premise only shows post-treatment outcomes, not causal evidence of LDL reduction.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "9",
    "premise": "Outcome: Rate of wound healing at Day 14 following topical application of silver sulfadiazine. 40% (8/20) of wounds showed full epithelialization by Day 14. Time frame: 14 days.",
    "statement": "Silver sulfadiazine accelerates wound healing within two weeks.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T (silver sulfadiazine) and Y (wound healing acceleration). The statement makes a causal claim about T accelerating Y.\n2. The premise reports 40% full epithelialization in the intervention group but lacks:\n   - Baseline healing rates without treatment\n   - Control group data for comparison\n3. Without comparative evidence (e.g., lower healing rates in untreated wounds), we cannot confirm causation - this could reflect natural healing progression rather than treatment effect.\n4. The premise only shows a single-arm outcome, violating the requirement for causal claims to have a comparator (core principle 2).\n5. Correlation (40% healing with treatment) \u2260 causation without evidence this rate exceeds expected/natural healing rates.\nConclusion: Insufficient evidence to support or refute the causal claim \u2192 neutral.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T (silver sulfadiazine) and Y (wound healing acceleration). The statement makes a causal claim about T accelerating Y.\n2. The premise reports 40% full epithelialization in the intervention group but lacks:\n   - Baseline healing rates without treatment\n   - Control group data for comparison\n3. Without comparative evidence (e.g., lower healing rates in untreated wounds), we cannot confirm causation - this could reflect natural healing progression rather than treatment effect.\n4. The premise only shows a single-arm outcome, violating the requirement for causal claims to have a comparator (core principle 2).\n5. Correlation (40% healing with treatment) \u2260 causation without evidence this rate exceeds expected/natural healing rates.\nConclusion: Insufficient evidence to support or refute the causal claim \u2192 neutral.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "10",
    "premise": "Outcome: Percentage of participants with pain reduction \u226530% on a 10-point scale at Week 6 following treatment with oral tramadol. 65% (13/20) met the pain reduction threshold. No control group included.",
    "statement": "Oral tramadol reduced pain levels significantly by Week 6.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. T = oral tramadol, Y = pain reduction. The statement makes a causal claim (T reduced Y).\n2. Premise reports 65% of participants achieved \u226530% pain reduction post-treatment but explicitly states 'No control group included'.\n3. Without a control group or baseline comparison data (e.g., pre-treatment pain levels), we cannot establish whether the observed effect is attributable to tramadol versus natural variation/placebo effect.\n4. While pain reduction threshold implies comparison to baseline measurements, the absence of baseline statistics (e.g., mean baseline pain score) and control group makes causal attribution impossible to confirm.\n5. Correlative evidence (pain reduction after administration) exists, but causal claims require evidence beyond temporal association when no comparator exists.\n6. Neutral because the premise lacks the necessary control/baseline comparison to support or refute causation.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. T = oral tramadol, Y = pain reduction. The statement makes a causal claim (T reduced Y).\n2. Premise reports 65% of participants achieved \u226530% pain reduction post-treatment but explicitly states 'No control group included'.\n3. Without a control group or baseline comparison data (e.g., pre-treatment pain levels), we cannot establish whether the observed effect is attributable to tramadol versus natural variation/placebo effect.\n4. While pain reduction threshold implies comparison to baseline measurements, the absence of baseline statistics (e.g., mean baseline pain score) and control group makes causal attribution impossible to confirm.\n5. Correlative evidence (pain reduction after administration) exists, but causal claims require evidence beyond temporal association when no comparator exists.\n6. Neutral because the premise lacks the necessary control/baseline comparison to support or refute causation.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "11",
    "premise": "78-year-old patient with stage IV HER2-positive breast cancer receiving daily paclitaxel at 315 mg/m\u00b2 for 12 weeks, along with standard trastuzumab therapy (initial loading dose of 4 mg/kg followed by 2 mg/kg weekly for 12 weeks, then 6 mg/kg every 3 weeks for 40 weeks).",
    "statement": "The patient is expected to experience clinical benefit from their treatment regimen, leading to disease stabilization and improved overall prognosis.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: Premise describes stage IV HER2+ breast cancer treatment with paclitaxel (315 mg/m\u00b2 daily \u00d712w) + trastuzumab (standard dosing). Statement claims clinical benefit.\n2. Verify dosing validity: Paclitaxel's standard dosing is weekly (80-100 mg/m\u00b2) or q3w (175-250 mg/m\u00b2). Daily 315 mg/m\u00b2 exceeds maximum tolerated cumulative doses (severe toxicity expected).\n3. Check drug interaction logic: While trastuzumab is HER2-targeted standard care, the paclitaxel schedule/dose violates pharmacokinetic safety thresholds (daily administration at this dose causes fatal bone marrow suppression).\n4. Dependency analysis: Incorrect paclitaxel administration invalidates the treatment's therapeutic intent - toxicity would prevent clinical benefit. This creates a fundamental contradiction between stated outcome and treatment reality.\n5. Conclusion: Impossible combination of dose/schedule makes clinical benefit biologically implausible.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Premise describes stage IV HER2+ breast cancer treatment with paclitaxel (315 mg/m\u00b2 daily \u00d712w) + trastuzumab (standard dosing). Statement claims clinical benefit.\n2. Verify dosing validity: Paclitaxel's standard dosing is weekly (80-100 mg/m\u00b2) or q3w (175-250 mg/m\u00b2). Daily 315 mg/m\u00b2 exceeds maximum tolerated cumulative doses (severe toxicity expected).\n3. Check drug interaction logic: While trastuzumab is HER2-targeted standard care, the paclitaxel schedule/dose violates pharmacokinetic safety thresholds (daily administration at this dose causes fatal bone marrow suppression).\n4. Dependency analysis: Incorrect paclitaxel administration invalidates the treatment's therapeutic intent - toxicity would prevent clinical benefit. This creates a fundamental contradiction between stated outcome and treatment reality.\n5. Conclusion: Impossible combination of dose/schedule makes clinical benefit biologically implausible.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "12",
    "premise": "65-year-old male with non-Hodgkin lymphoma receiving cyclophosphamide at 415mg/m\u00b2 intravenously on Days 1\u20135 of each 21-day cycle, for 4 cycles.",
    "statement": "The treatment is expected to result in some reduction in lymph node size, with durable response and extended survival.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "The premise describes a 65-year-old male with non-Hodgkin lymphoma receiving cyclophosphamide at 415mg/m\u00b2 intravenously on Days 1\u20135 of a 21-day cycle for 4 cycles. The statement claims the treatment will result in reduced lymph node size, durable response, and extended survival. Cyclophosphamide is a standard chemotherapy agent for NHL, but its efficacy in monotherapy (as implied here) is typically lower than in combination regimens (e.g., CHOP). The dose (415mg/m\u00b2/day \u00d75 days = 2075mg/m\u00b2/cycle) exceeds typical single-cycle doses in combination therapies (e.g., 750mg/m\u00b2/cycle in CHOP), but the schedule (5-day split) and monotherapy context are non-standard. While cyclophosphamide may induce some response, the premise does not provide evidence for 'durable response' or 'extended survival' in this specific regimen. The statement\u2019s claims depend on unstated efficacy assumptions, making them neither directly entailed nor contradicted by the premise\u2019s factual details.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "The premise describes a 65-year-old male with non-Hodgkin lymphoma receiving cyclophosphamide at 415mg/m\u00b2 intravenously on Days 1\u20135 of a 21-day cycle for 4 cycles. The statement claims the treatment will result in reduced lymph node size, durable response, and extended survival. Cyclophosphamide is a standard chemotherapy agent for NHL, but its efficacy in monotherapy (as implied here) is typically lower than in combination regimens (e.g., CHOP). The dose (415mg/m\u00b2/day \u00d75 days = 2075mg/m\u00b2/cycle) exceeds typical single-cycle doses in combination therapies (e.g., 750mg/m\u00b2/cycle in CHOP), but the schedule (5-day split) and monotherapy context are non-standard. While cyclophosphamide may induce some response, the premise does not provide evidence for 'durable response' or 'extended survival' in this specific regimen. The statement\u2019s claims depend on unstated efficacy assumptions, making them neither directly entailed nor contradicted by the premise\u2019s factual details.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": false,
    "error_info": []
  },
  {
    "problem_id": "13",
    "premise": "68-year-old female with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min/1.73m\u00b2) receiving metformin 1000mg twice daily.",
    "statement": "The treatment is expected to improve glycemic control, reduce cardiovascular risk, and provide long-term kidney protection.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: 68F, T2DM, CKD (eGFR 25), metformin 1000mg BID.\n2. Metformin is contraindicated in eGFR <30 mL/min/1.73m\u00b2 per FDA guidelines (risk of lactic acidosis).\n3. Chronic use in this renal context would contradict standard of care, making the treatment itself invalid.\n4. While metformin can improve glycemic control in appropriate patients, its contraindicated use here creates a dependency violation (CKD stage 4 + full-dose metformin = unsafe therapy).\n5. Cardiovascular risk reduction and kidney protection claims depend on valid therapy - contraindicated regimen cannot achieve these outcomes.\n6. Violation of drug-diagnosis (renal function) interaction invalidates all stated benefits \u2192 contradiction.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: 68F, T2DM, CKD (eGFR 25), metformin 1000mg BID.\n2. Metformin is contraindicated in eGFR <30 mL/min/1.73m\u00b2 per FDA guidelines (risk of lactic acidosis).\n3. Chronic use in this renal context would contradict standard of care, making the treatment itself invalid.\n4. While metformin can improve glycemic control in appropriate patients, its contraindicated use here creates a dependency violation (CKD stage 4 + full-dose metformin = unsafe therapy).\n5. Cardiovascular risk reduction and kidney protection claims depend on valid therapy - contraindicated regimen cannot achieve these outcomes.\n6. Violation of drug-diagnosis (renal function) interaction invalidates all stated benefits \u2192 contradiction.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "14",
    "premise": "45\u2011year\u2011old patient with squamous cell carcinoma receiving weekly cetuximab at 250mg/m\u00b2 and cisplatin at 250mg/m\u00b2 daily for 7 days.",
    "statement": "The patient is expected to show partial regression of the tumor, with a favorable clinical response and improved progression-free survival.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: Cetuximab 250mg/m\u00b2 weekly (correct maintenance dose after loading) + cisplatin 250mg/m\u00b2 daily \u00d77 days (1750mg/m\u00b2 total).\n2. Cisplatin standard dosing: 50-100mg/m\u00b2 per cycle (not per day). Daily \u00d77 at this dose exceeds maximum tolerated cumulative doses (severe nephrotoxicity/neurotoxicity expected).\n3. Dependency violation: Extreme cisplatin overdose would cause treatment-limiting toxicity rather than tumor response. Safe/effective drug-dose-schedule combination is violated.\n4. No evidence that this toxic regimen would achieve partial regression or improved PFS. Contraindicated dosing invalidates the clinical benefit claim.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Cetuximab 250mg/m\u00b2 weekly (correct maintenance dose after loading) + cisplatin 250mg/m\u00b2 daily \u00d77 days (1750mg/m\u00b2 total).\n2. Cisplatin standard dosing: 50-100mg/m\u00b2 per cycle (not per day). Daily \u00d77 at this dose exceeds maximum tolerated cumulative doses (severe nephrotoxicity/neurotoxicity expected).\n3. Dependency violation: Extreme cisplatin overdose would cause treatment-limiting toxicity rather than tumor response. Safe/effective drug-dose-schedule combination is violated.\n4. No evidence that this toxic regimen would achieve partial regression or improved PFS. Contraindicated dosing invalidates the clinical benefit claim.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "15",
    "premise": "72-year-old patient with advanced non-small cell lung cancer receiving cisplatin at 120mg/m\u00b2 on Day 1 and vinorelbine 30mg/m\u00b2 on Days 1 and 8 of a 21-day cycle, repeated for 6 cycles.",
    "statement": "The patient is expected to experience tumor response with improved respiratory function and overall clinical benefit.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "The premise describes a 72-year-old NSCLC patient receiving cisplatin + vinorelbine at standard doses/schedule (120mg/m\u00b2 Day 1 cisplatin, 30mg/m\u00b2 Days 1+8 vinorelbine, 21-day cycles \u00d76). This combination is an established first-line regimen for advanced NSCLC with documented tumor response rates (~25-30%) and clinical benefit in eligible patients. The statement asserts expected tumor response, improved respiratory function, and clinical benefit. While individual responses vary, the regimen's known efficacy profile supports these outcomes as clinically expected when administered correctly to appropriate candidates. No contradictions in dosing, scheduling, or patient factors (age alone without comorbidities/contraindications doesn't preclude benefit) are present. The interdependency of drug efficacy + proper administration is maintained.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "incorrect",
        "overall_verification": false
      },
      {
        "reasoning": "1. Extract factors: Regimen (cisplatin + vinorelbine at standard doses/schedule), patient age (72), NSCLC stage (advanced).\n2. Efficacy facts: The regimen is known to produce tumor response (~25-30%) and clinical benefit in line with clinical literature (supported by premise/regularities).\n3. Dependency analysis: 'Improved respiratory function' requires tumor shrinkage alleviating airway obstruction. The premise does not specify tumor location/airway involvement or direct evidence of respiratory improvement as a documented outcome of this regimen.\n4. All-conditions test: Tumor response and clinical benefit are supported, but respiratory improvement lacks premise-supported causal linkage. Violation of joint satisfaction occurs for one component.\n5. No contradictions in dosing/eligibility, but unsupported extrapolation for respiratory outcome introduces neutrality per CTNLI principles (no invention of unstated outcome dependencies).",
        "pred": "neutral"
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Regimen (cisplatin + vinorelbine at standard doses/schedule), patient age (72), NSCLC stage (advanced).\n2. Efficacy facts: The regimen is known to produce tumor response (~25-30%) and clinical benefit in line with clinical literature (supported by premise/regularities).\n3. Dependency analysis: 'Improved respiratory function' requires tumor shrinkage alleviating airway obstruction. The premise does not specify tumor location/airway involvement or direct evidence of respiratory improvement as a documented outcome of this regimen.\n4. All-conditions test: Tumor response and clinical benefit are supported, but respiratory improvement lacks premise-supported causal linkage. Violation of joint satisfaction occurs for one component.\n5. No contradictions in dosing/eligibility, but unsupported extrapolation for respiratory outcome introduces neutrality per CTNLI principles (no invention of unstated outcome dependencies).",
      "pred": "neutral"
    },
    "is_correct": false,
    "error_info": []
  },
  {
    "problem_id": "16",
    "premise": "53-year-old female with triple-negative breast cancer receiving doxorubicin 90mg/m\u00b2 every week for 8 weeks.",
    "statement": "The patient is expected to respond well to the regimen, with meaningful tumor shrinkage and sustained clinical benefit.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: doxorubicin 90mg/m\u00b2 weekly for 8 weeks (total cumulative dose = 720mg/m\u00b2).\n2. Clinical constraints: Maximum recommended lifetime cumulative doxorubicin dose is 450-550mg/m\u00b2 to avoid cardiotoxicity.\n3. Dependency violation: 720mg/m\u00b2 exceeds safe cumulative threshold \u2192 creates high risk of irreversible heart failure rather than clinical benefit.\n4. Triple-negative breast cancer context: While anthracyclines are used, this excessive dosing schedule directly contradicts safety guidelines.\n5. Statement about 'sustained clinical benefit' is incompatible with cardiotoxic overdose scenario \u2192 fundamental contradiction.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: doxorubicin 90mg/m\u00b2 weekly for 8 weeks (total cumulative dose = 720mg/m\u00b2).\n2. Clinical constraints: Maximum recommended lifetime cumulative doxorubicin dose is 450-550mg/m\u00b2 to avoid cardiotoxicity.\n3. Dependency violation: 720mg/m\u00b2 exceeds safe cumulative threshold \u2192 creates high risk of irreversible heart failure rather than clinical benefit.\n4. Triple-negative breast cancer context: While anthracyclines are used, this excessive dosing schedule directly contradicts safety guidelines.\n5. Statement about 'sustained clinical benefit' is incompatible with cardiotoxic overdose scenario \u2192 fundamental contradiction.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "17",
    "premise": "2-month-old infant diagnosed with metastatic melanoma receiving pembrolizumab 200mg intravenously every 3 weeks.",
    "statement": "The therapy is expected to induce an immune response against the tumor and improve the clinical outlook.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: Premise specifies a 2-month-old infant receiving pembrolizumab 200mg every 3 weeks. Statement claims expected therapeutic benefit.\n2. Dependency analysis: Pembrolizumab dosing in pediatrics requires weight-based calculation (2 mg/kg up to 200mg). A 2-month-old infant (~4-5kg) would require 8-10mg, making 200mg a 20-25x overdose.\n3. Age constraint: Pembrolizumab is not FDA-approved for infants <6 months. Immune system immaturity in neonates alters drug response dynamics.\n4. Interaction effect: Extreme overdose would likely cause severe immune-related adverse events rather than therapeutic benefit.\n5. Clinical context: No evidence exists for pembrolizumab efficacy/safety in infants with melanoma, making claimed outcome biologically implausible.\n6. Violation: Multiple critical constraints (dose-age-weight mismatch, lack of approval/evidence) invalidate the statement's claim.",
        "pred": "contradiction",
        "fact_verification": "incorrect",
        "reasoning_verification": "incorrect",
        "overall_verification": false
      },
      {
        "reasoning": "1. Extract factors: Premise specifies a 2-month-old infant receiving pembrolizumab 200mg every 3 weeks. Statement claims expected therapeutic benefit (immune response + improved outlook).\n2. Dependency analysis: Pembrolizumab's mechanism (immune activation) could theoretically induce a tumor response. However, the premise dose (200mg) aligns with adult regimens, not pediatric norms. While weight is unspecified, a 2-month-old's typical weight range (3-6kg) makes 200mg a severe overdose (33-66 mg/kg vs. standard 2 mg/kg).\n3. Violation test: Extreme overdose introduces a dependency conflict - toxicity (cytokine storm, organ damage) would dominate over therapeutic benefit, directly contradicting 'improved clinical outlook'.\n4. All-conditions test: The statement requires simultaneous validity of (a) immune response induction and (b) clinical improvement. While (a) is mechanistically plausible, (b) is invalidated by dose-driven harm.\n5. No invention: Avoid assuming FDA approval status or exact pharmacokinetics. Rely on premise dose + age + known toxicity thresholds (overdose severity is implicit from standard 2 mg/kg guideline referenced in drug labeling).",
        "pred": "contradiction"
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Premise specifies a 2-month-old infant receiving pembrolizumab 200mg every 3 weeks. Statement claims expected therapeutic benefit (immune response + improved outlook).\n2. Dependency analysis: Pembrolizumab's mechanism (immune activation) could theoretically induce a tumor response. However, the premise dose (200mg) aligns with adult regimens, not pediatric norms. While weight is unspecified, a 2-month-old's typical weight range (3-6kg) makes 200mg a severe overdose (33-66 mg/kg vs. standard 2 mg/kg).\n3. Violation test: Extreme overdose introduces a dependency conflict - toxicity (cytokine storm, organ damage) would dominate over therapeutic benefit, directly contradicting 'improved clinical outlook'.\n4. All-conditions test: The statement requires simultaneous validity of (a) immune response induction and (b) clinical improvement. While (a) is mechanistically plausible, (b) is invalidated by dose-driven harm.\n5. No invention: Avoid assuming FDA approval status or exact pharmacokinetics. Rely on premise dose + age + known toxicity thresholds (overdose severity is implicit from standard 2 mg/kg guideline referenced in drug labeling).",
      "pred": "contradiction"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "18",
    "premise": "59-year-old male with relapsed acute lymphoblastic leukemia receiving methotrexate 250mg/m\u00b2 intravenously daily for 10 consecutive days.",
    "statement": "The treatment is expected to reduce leukemic burden and improve survival prospects.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: Premise describes relapsed ALL patient receiving methotrexate 250mg/m\u00b2 IV daily \u00d710 days. Statement claims this regimen reduces leukemic burden and improves survival.\n2. Clinical dependency analysis: High-dose methotrexate (\u2265500mg/m\u00b2) requires leucovorin rescue and hydration to prevent toxicity. The described 250mg/m\u00b2 daily \u00d710 exceeds typical ALL protocols (usually 1-5g/m\u00b2 as 24hr infusion with rescue, repeated weekly).\n3. Schedule interaction: Daily administration for 10 days without rescue would cause cumulative toxicity (myelosuppression, nephrotoxicity), making the regimen non-viable and counterproductive.\n4. Survival impact: An impossible/impaired regimen due to toxicity cannot achieve therapeutic benefit. This creates a dependency violation between stated dose/schedule and expected outcomes.\n5. Conclusion: The described treatment parameters contradict clinical feasibility, thereby contradicting the therapeutic benefit claim.",
        "pred": "contradiction",
        "fact_verification": "incorrect",
        "reasoning_verification": "correct",
        "overall_verification": false
      },
      {
        "reasoning": "1. Extract factors: Relapsed ALL patient receiving methotrexate 250mg/m\u00b2 IV daily for 10 days. Statement asserts leukemic burden reduction and survival improvement.\n2. Clinical dependency analysis: Standard ALL protocols use methotrexate with leucovorin rescue for regimens exceeding 24-36 hours. The premise specifies no supportive measures.\n3. Schedule interaction: Daily administration for 10 consecutive days (without explicit premise-stated rescue/hydration) violates standard practice, as cumulative toxicity (myelosuppression, nephrotoxicity) would render the regimen non-viable regardless of dose.\n4. Survival impact: A regimen causing severe adverse effects without therapeutic drug exposure (due to mandatory discontinuation from toxicity) cannot achieve the claimed benefits.\n5. Violation test: The described parameters (prolonged schedule without rescue) contradict clinical feasibility, thereby contradicting the therapeutic outcome claim.",
        "pred": "contradiction"
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Relapsed ALL patient receiving methotrexate 250mg/m\u00b2 IV daily for 10 days. Statement asserts leukemic burden reduction and survival improvement.\n2. Clinical dependency analysis: Standard ALL protocols use methotrexate with leucovorin rescue for regimens exceeding 24-36 hours. The premise specifies no supportive measures.\n3. Schedule interaction: Daily administration for 10 consecutive days (without explicit premise-stated rescue/hydration) violates standard practice, as cumulative toxicity (myelosuppression, nephrotoxicity) would render the regimen non-viable regardless of dose.\n4. Survival impact: A regimen causing severe adverse effects without therapeutic drug exposure (due to mandatory discontinuation from toxicity) cannot achieve the claimed benefits.\n5. Violation test: The described parameters (prolonged schedule without rescue) contradict clinical feasibility, thereby contradicting the therapeutic outcome claim.",
      "pred": "contradiction"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "19",
    "premise": "64-year-old patient with advanced pancreatic cancer receiving gemcitabine 1250mg/m\u00b2 intravenously on Days 1\u20135 every 21 days for four cycles.",
    "statement": "The treatment is expected to relieve symptoms and prolong overall survival.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: Premise specifies gemcitabine 1250mg/m\u00b2 Days 1\u20135 q21d for advanced pancreatic cancer. Statement claims expected survival benefit and symptom relief.\n2. Clinical knowledge check: Standard gemcitabine regimen for pancreatic cancer is 1000mg/m\u00b2 weekly (Days 1,8,15 q28d) - the 5-day schedule in premise is non-standard.\n3. Dependency analysis: Survival benefit/symptom relief evidence exists only for standard schedule. The premise's intensified regimen (higher cumulative dose over 5 days) would likely increase toxicity without proven survival benefit.\n4. Constraint violation: The stated schedule-dose combination lacks evidence for achieving the claimed outcomes, creating a therapeutic mismatch.\n5. Conclusion: Statement contradicts evidence-based expectations for this specific regimen.",
        "pred": "contradiction",
        "fact_verification": "incorrect",
        "reasoning_verification": "correct",
        "overall_verification": false
      },
      {
        "reasoning": "1. Extract factors: Premise specifies gemcitabine 1250mg/m\u00b2 on Days 1\u20135 every 21 days for advanced pancreatic cancer. Statement claims expected symptom relief and survival prolongation.\n2. Clinical evidence check: Standard validated regimen uses 1000mg/m\u00b2 weekly (Days 1,8,15 q28d). The premise's 5-consecutive-day schedule (q21d) deviates from evidence-based administration patterns.\n3. Dependency analysis: Survival benefit and symptom relief outcomes are only demonstrated for the weekly schedule in clinical trials. No studies validate efficacy claims for the premise's compressed 5-day administration structure.\n4. Constraint violation: Therapeutic outcomes are schedule-dependent. The statement's claims require adherence to the evidence-based schedule, which the premise violates through its non-standard cycle design.\n5. Conclusion: Absent evidence linking the premise's specific regimen structure to the claimed benefits, the statement contradicts clinical validation requirements.",
        "pred": "contradiction"
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Premise specifies gemcitabine 1250mg/m\u00b2 on Days 1\u20135 every 21 days for advanced pancreatic cancer. Statement claims expected symptom relief and survival prolongation.\n2. Clinical evidence check: Standard validated regimen uses 1000mg/m\u00b2 weekly (Days 1,8,15 q28d). The premise's 5-consecutive-day schedule (q21d) deviates from evidence-based administration patterns.\n3. Dependency analysis: Survival benefit and symptom relief outcomes are only demonstrated for the weekly schedule in clinical trials. No studies validate efficacy claims for the premise's compressed 5-day administration structure.\n4. Constraint violation: Therapeutic outcomes are schedule-dependent. The statement's claims require adherence to the evidence-based schedule, which the premise violates through its non-standard cycle design.\n5. Conclusion: Absent evidence linking the premise's specific regimen structure to the claimed benefits, the statement contradicts clinical validation requirements.",
      "pred": "contradiction"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "20",
    "premise": "60-year-old male with head and neck squamous cell carcinoma receiving cisplatin 250mg/m\u00b2 daily for 7 consecutive days along with standard radiation therapy.",
    "statement": "The regimen is expected to enhance tumor control and improve survival outcomes.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: cisplatin 250mg/m\u00b2 daily for 7 days + radiation therapy for HNSCC.\n2. Clinical knowledge check: Standard concurrent cisplatin regimens for head/neck cancer are 100mg/m\u00b2 every 3 weeks or lower weekly doses. The described regimen (250mg/m\u00b2 \u00d77 days = 1750mg/m\u00b2 total) exceeds maximum cumulative dose thresholds (typically 300-400mg/m\u00b2 per cycle).\n3. Dependency analysis: Extreme overdosing would cause severe toxicity (renal failure, ototoxicity, myelosuppression) requiring treatment discontinuation, contradicting improved outcomes.\n4. Interaction effect: This schedule violates safe dosing parameters and clinical protocols, making enhanced tumor control/survival biologically implausible due to treatment-limiting toxicity.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: cisplatin 250mg/m\u00b2 daily for 7 days + radiation therapy for HNSCC.\n2. Clinical knowledge check: Standard concurrent cisplatin regimens for head/neck cancer are 100mg/m\u00b2 every 3 weeks or lower weekly doses. The described regimen (250mg/m\u00b2 \u00d77 days = 1750mg/m\u00b2 total) exceeds maximum cumulative dose thresholds (typically 300-400mg/m\u00b2 per cycle).\n3. Dependency analysis: Extreme overdosing would cause severe toxicity (renal failure, ototoxicity, myelosuppression) requiring treatment discontinuation, contradicting improved outcomes.\n4. Interaction effect: This schedule violates safe dosing parameters and clinical protocols, making enhanced tumor control/survival biologically implausible due to treatment-limiting toxicity.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "21",
    "premise": "67-year-old male presented with mild lower urinary tract symptoms, including frequency and a weak urinary stream. Digital rectal examination was unremarkable. Blood tests revealed a PSA level of 9.2 ng/mL. The case was reviewed by Consultant Urologist Dr. M. Rahman, who made a diagnosis of prostate cancer based on the PSA result. The patient was informed of the diagnosis and referred to oncology for further management. No imaging or biopsy was arranged at this stage.",
    "statement": "The patient has prostate cancer",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Highest evidence (PSA 9.2 ng/mL) shows elevated value but is insufficient alone for prostate cancer diagnosis per clinical standards. 2. Consultant's diagnosis (lower evidence tier) conflicts with absence of biopsy/imaging (gold-standard diagnostic methods in hierarchy). 3. Normal DRE and lack of histopathological confirmation contradict the diagnosis. 4. Reject clinician opinion due to missing objective confirmation required by diagnostic criteria.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Highest evidence (PSA 9.2 ng/mL) shows elevated value but is insufficient alone for prostate cancer diagnosis per clinical standards. 2. Consultant's diagnosis (lower evidence tier) conflicts with absence of biopsy/imaging (gold-standard diagnostic methods in hierarchy). 3. Normal DRE and lack of histopathological confirmation contradict the diagnosis. 4. Reject clinician opinion due to missing objective confirmation required by diagnostic criteria.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "22",
    "premise": "A 34-year-old male presents to the emergency department with sudden onset chest pain radiating to his left arm, shortness of breath, and diaphoresis. ECG shows ST-elevation in leads II, III, and aVF. Troponin is markedly elevated. The attending physician rules out myocardial infarction and concludes that the patient is experiencing heartburn due to spicy food eaten earlier. The patient is discharged with antacids and advised to avoid chili.",
    "statement": "The patient is experiencing heartburn.",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "Objective evidence (ECG showing ST-elevation in inferior leads II/III/aVF and elevated troponin) strongly indicates myocardial infarction, which is higher in the evidence hierarchy than the physician's opinion. The diagnosis of heartburn directly contradicts these instrumented findings. ST-elevation + elevated troponin meets diagnostic criteria for STEMI and cannot be explained by heartburn.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "Objective evidence (ECG showing ST-elevation in inferior leads II/III/aVF and elevated troponin) strongly indicates myocardial infarction, which is higher in the evidence hierarchy than the physician's opinion. The diagnosis of heartburn directly contradicts these instrumented findings. ST-elevation + elevated troponin meets diagnostic criteria for STEMI and cannot be explained by heartburn.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "23",
    "premise": "A 66-year-old man with no significant past medical history presents with severe, tearing chest pain radiating to the back. Blood pressure is markedly different between arms. The emergency physician diagnoses musculoskeletal pain and prescribes NSAIDs.",
    "statement": "The patient has an aortic dissection.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "Objective findings (tearing chest pain with back radiation, interarm BP difference) are higher in evidence hierarchy than clinician opinion. These classic dissection signs contradict the musculoskeletal diagnosis. Aortic dissection is entailed by the objective evidence despite conflicting clinician interpretation.",
        "pred": "entailment",
        "fact_verification": "fact_verification_error",
        "reasoning_verification": "reasoning_verification_error",
        "overall_verification": false
      },
      {
        "reasoning": "1. Parse premise: Objective findings (tearing chest pain with back radiation, interarm BP difference - instrumented data) vs. clinician's musculoskeletal diagnosis (opinion).\n2. Apply evidence hierarchy: Instrumented BP measurement and classic symptom presentation (tearing pain) outrank clinician opinion.\n3. Resolve conflict by removing lowest-credibility evidence (physician's diagnosis) as it directly contradicts higher-tier objective signs of dissection.\n4. Remaining evidence (tearing pain + BP differential) satisfies diagnostic criteria for aortic dissection.\n5. Statement is entailed by highest-credibility evidence despite conflicting clinician interpretation.",
        "pred": "entailment"
      }
    ],
    "solution_final": {
      "reasoning": "1. Parse premise: Objective findings (tearing chest pain with back radiation, interarm BP difference - instrumented data) vs. clinician's musculoskeletal diagnosis (opinion).\n2. Apply evidence hierarchy: Instrumented BP measurement and classic symptom presentation (tearing pain) outrank clinician opinion.\n3. Resolve conflict by removing lowest-credibility evidence (physician's diagnosis) as it directly contradicts higher-tier objective signs of dissection.\n4. Remaining evidence (tearing pain + BP differential) satisfies diagnostic criteria for aortic dissection.\n5. Statement is entailed by highest-credibility evidence despite conflicting clinician interpretation.",
      "pred": "entailment"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "24",
    "premise": "A 25-year-old female comes in with fever, flank pain, and dysuria. Urine culture is positive for E. coli. Despite this, the physician suggests that the pain is likely due to a pulled muscle and no antibiotics are prescribed.",
    "statement": "The patient has a urinary tract infection.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. The premise contains two conflicting claims: (a) urine culture positive for E. coli (instrumented lab result, highest evidence tier) and (b) physician's opinion attributing pain to musculoskeletal cause (lower evidence tier).\n2. E. coli in urine culture with UTI symptoms (fever, dysuria, flank pain) objectively meets diagnostic criteria for urinary tract infection regardless of clinical opinion.\n3. Physician's alternative explanation doesn't invalidate the microbiological evidence. Antibiotic prescription status is irrelevant to infection presence.\n4. The statement is directly supported by the highest-tier objective evidence (culture result + symptoms).",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. The premise contains two conflicting claims: (a) urine culture positive for E. coli (instrumented lab result, highest evidence tier) and (b) physician's opinion attributing pain to musculoskeletal cause (lower evidence tier).\n2. E. coli in urine culture with UTI symptoms (fever, dysuria, flank pain) objectively meets diagnostic criteria for urinary tract infection regardless of clinical opinion.\n3. Physician's alternative explanation doesn't invalidate the microbiological evidence. Antibiotic prescription status is irrelevant to infection presence.\n4. The statement is directly supported by the highest-tier objective evidence (culture result + symptoms).",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "25",
    "premise": "A 59-year-old woman presents with a persistent cough, weight loss, and night sweats. Chest X-ray shows a large mass in the right upper lobe. The clinician diagnoses her with pneumonia and prescribes antibiotics without further workup.",
    "statement": "The patient has lung cancer.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Parse premise: Symptoms (cough, weight loss, night sweats), chest X-ray (mass in RUL), clinician diagnosis (pneumonia).\n2. Evidence hierarchy: Chest X-ray (instrumented data) > clinician opinion.\n3. Conflict: X-ray mass (suggestive of malignancy) vs pneumonia diagnosis (requires infiltrates).\n4. Resolve: X-ray evidence overrules clinician opinion due to hierarchy.\n5. Lung cancer is strongly supported by X-ray mass + B symptoms (weight loss/night sweats) via clinical regularities.\n6. Clinician's pneumonia diagnosis is contradicted by imaging findings.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Parse premise: Symptoms (cough, weight loss, night sweats), chest X-ray (mass in RUL), clinician diagnosis (pneumonia).\n2. Evidence hierarchy: Chest X-ray (instrumented data) > clinician opinion.\n3. Conflict: X-ray mass (suggestive of malignancy) vs pneumonia diagnosis (requires infiltrates).\n4. Resolve: X-ray evidence overrules clinician opinion due to hierarchy.\n5. Lung cancer is strongly supported by X-ray mass + B symptoms (weight loss/night sweats) via clinical regularities.\n6. Clinician's pneumonia diagnosis is contradicted by imaging findings.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": false,
    "error_info": []
  },
  {
    "problem_id": "26",
    "premise": "A 38-year-old woman presents with episodes of palpitations, anxiety, and sweating. Her blood pressure is 180/110 mm Hg. No labs or imaging are done. The physician diagnoses panic disorder and refers her to a therapist.",
    "statement": "The patient has panic disorder.",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "The physician's diagnosis of panic disorder (clinician opinion) conflicts with the objective finding of hypertensive crisis (180/110 mm Hg). No labs/imaging were performed to rule out organic causes like pheochromocytoma that could explain both hypertension and adrenergic symptoms. Per evidence hierarchy, instrumented BP measurement (highest tier) contradicts the lower-tier clinical opinion. Diagnosis without excluding medical mimics makes the claim unreliable.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "The physician's diagnosis of panic disorder (clinician opinion) conflicts with the objective finding of hypertensive crisis (180/110 mm Hg). No labs/imaging were performed to rule out organic causes like pheochromocytoma that could explain both hypertension and adrenergic symptoms. Per evidence hierarchy, instrumented BP measurement (highest tier) contradicts the lower-tier clinical opinion. Diagnosis without excluding medical mimics makes the claim unreliable.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "27",
    "premise": "The patient reported that her persistent cough and weight loss were due to seasonal allergies. However, further workup revealed a mass in the left lung and a biopsy confirmed adenocarcinoma.",
    "statement": "The patient has seasonal allergies.",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Premise contains conflicting claims: patient's attribution of symptoms to seasonal allergies (self-report) vs. objective findings of lung adenocarcinoma (biopsy).\n2. Evidence hierarchy prioritizes biopsy-confirmed adenocarcinoma (instrumented data) over patient self-report.\n3. While adenocarcinoma explains the symptoms, seasonal allergy presence itself isn't directly measured (no allergy testing reported).\n4. Patient's claim about allergies remains uncorroborated but not impossible (allergies could coexist with cancer).\n5. No direct contradiction about allergy existence, only about symptom causation.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Premise contains conflicting claims: patient's attribution of symptoms to seasonal allergies (self-report) vs. objective findings of lung adenocarcinoma (biopsy).\n2. Evidence hierarchy prioritizes biopsy-confirmed adenocarcinoma (instrumented data) over patient self-report.\n3. While adenocarcinoma explains the symptoms, seasonal allergy presence itself isn't directly measured (no allergy testing reported).\n4. Patient's claim about allergies remains uncorroborated but not impossible (allergies could coexist with cancer).\n5. No direct contradiction about allergy existence, only about symptom causation.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": false,
    "error_info": []
  },
  {
    "problem_id": "28",
    "premise": "A 60-year-old male underwent knee replacement surgery on June 5, 2023. At his postoperative follow-up on May 30, 2023, he reported no complications and good mobility.",
    "statement": "The patient followed up after his knee replacement surgery.",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "The premise contains conflicting temporal claims: surgery occurred June 5, 2023 (instrumented date) and postoperative follow-up occurred May 30, 2023 (instrumented date). Postoperative follow-up cannot precede surgery. Both claims are instrumented data (highest evidence tier) but mutually exclusive. This creates unresolvable ontological contradiction. The statement 'followed up after surgery' is contradicted by the timeline where follow-up (May 30) precedes surgery (June 5).",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "The premise contains conflicting temporal claims: surgery occurred June 5, 2023 (instrumented date) and postoperative follow-up occurred May 30, 2023 (instrumented date). Postoperative follow-up cannot precede surgery. Both claims are instrumented data (highest evidence tier) but mutually exclusive. This creates unresolvable ontological contradiction. The statement 'followed up after surgery' is contradicted by the timeline where follow-up (May 30) precedes surgery (June 5).",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "29",
    "premise": "A 50-year-old man presents with worsening fatigue, hypotension, and hyperpigmentation of the skin. Laboratory results reveal low cortisol and elevated ACTH levels. The physician diagnoses the patient with depression and prescribes SSRIs.",
    "statement": "The patient has Addison's disease.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "Objective findings (low cortisol, elevated ACTH, hyperpigmentation, hypotension) strongly support Addison's disease per diagnostic criteria. The physician's depression diagnosis is a lower-hierarchy opinion contradicted by lab values. Resolving via evidence hierarchy: prioritize labs/symptoms over clinician opinion. Statement aligns with higher-tier evidence.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "Objective findings (low cortisol, elevated ACTH, hyperpigmentation, hypotension) strongly support Addison's disease per diagnostic criteria. The physician's depression diagnosis is a lower-hierarchy opinion contradicted by lab values. Resolving via evidence hierarchy: prioritize labs/symptoms over clinician opinion. Statement aligns with higher-tier evidence.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "30",
    "premise": "A 22-year-old woman arrives at the emergency department after fainting during exercise. ECG reveals a prolonged QT interval. Her symptoms are attributed to dehydration, and she is discharged with fluids and electrolyte tablets.",
    "statement": "The patient has long QT syndrome.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Premise contains instrumented data (ECG showing prolonged QT interval - objective measurement) and clinician opinion (attribution to dehydration).\n2. Long QT syndrome diagnosis requires persistent/recurrent prolonged QT intervals and clinical correlation, not just a single measurement.\n3. Dehydration (with electrolyte imbalances) can cause transient QT prolongation, which aligns with clinician's interpretation and treatment (fluids/electrolytes).\n4. No evidence of repeated ECGs, family history, or other diagnostic evaluations for congenital long QT syndrome.\n5. Clinician opinion (lower hierarchy) aligns with reversible cause (dehydration) rather than chronic syndrome.\n6. Statement claims definitive diagnosis (long QT syndrome) which contradicts premise's attribution to temporary dehydration-related QT prolongation.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Premise contains instrumented data (ECG showing prolonged QT interval - objective measurement) and clinician opinion (attribution to dehydration).\n2. Long QT syndrome diagnosis requires persistent/recurrent prolonged QT intervals and clinical correlation, not just a single measurement.\n3. Dehydration (with electrolyte imbalances) can cause transient QT prolongation, which aligns with clinician's interpretation and treatment (fluids/electrolytes).\n4. No evidence of repeated ECGs, family history, or other diagnostic evaluations for congenital long QT syndrome.\n5. Clinician opinion (lower hierarchy) aligns with reversible cause (dehydration) rather than chronic syndrome.\n6. Statement claims definitive diagnosis (long QT syndrome) which contradicts premise's attribution to temporary dehydration-related QT prolongation.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": false,
    "error_info": []
  },
  {
    "problem_id": "31",
    "premise": "Patient (52M), currently on holiday, presents with several months' history of nasal congestion (blocked, crusty), generalized fatigue, and widespread myalgia. Reports feeling generally unwell.",
    "statement": "The patient requires urgent outpatient evaluation.",
    "label": "entailment",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. Extract candidates: Chronic nasal congestion with crusting (possible granulomatosis with polyangiitis), systemic symptoms (fatigue/myalgia) suggesting vasculitis or autoimmune disease. No diagnostic workup mentioned. 2. Likelihood: Autoimmune conditions are less common but not excluded. Severity: Untreated GPA carries high risk of renal failure/pulmonary hemorrhage. 3. Risk comparison: While common causes (allergies) are more likely, the plausible existence of a high-risk undiagnosed condition (GPA) creates substantial expected harm. 4. Statement proposes urgent evaluation - appropriate given severe not-ruled-out risks. Discharging without workup would risk catastrophic deterioration.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract candidates: Chronic nasal congestion with crusting (possible granulomatosis with polyangiitis), systemic symptoms (fatigue/myalgia) suggesting vasculitis or autoimmune disease. No diagnostic workup mentioned. 2. Likelihood: Autoimmune conditions are less common but not excluded. Severity: Untreated GPA carries high risk of renal failure/pulmonary hemorrhage. 3. Risk comparison: While common causes (allergies) are more likely, the plausible existence of a high-risk undiagnosed condition (GPA) creates substantial expected harm. 4. Statement proposes urgent evaluation - appropriate given severe not-ruled-out risks. Discharging without workup would risk catastrophic deterioration.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "32",
    "premise": "A 40-year-old female presents with a mild fever and pain localized to the renal angle. She denies any coughing and her pulse is within normal limits. Based on her symptoms, she suspects she may have pyelonephritis.",
    "statement": "Pneumonia is ruled out for this patient",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. Extract candidates: The premise focuses on pyelonephritis (A: kidney infection) but mentions absence of cough (B: pneumonia not fully excluded).\n2. Likelihood: Pneumonia is less likely given absence of cough and normal pulse, but not definitively ruled out (atypical presentations exist).\n3. Severity: Pneumonia carries high severity (respiratory compromise, sepsis risk).\n4. Risk comparison: While low likelihood, high severity means pneumonia remains a non-trivial risk until excluded by chest imaging or other diagnostics.\n5. Statement evaluation: Claiming pneumonia is 'ruled out' contradicts risk principles - absence of key symptoms reduces likelihood but doesn't exclude this high-severity condition without confirmatory testing.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract candidates: The premise focuses on pyelonephritis (A: kidney infection) but mentions absence of cough (B: pneumonia not fully excluded).\n2. Likelihood: Pneumonia is less likely given absence of cough and normal pulse, but not definitively ruled out (atypical presentations exist).\n3. Severity: Pneumonia carries high severity (respiratory compromise, sepsis risk).\n4. Risk comparison: While low likelihood, high severity means pneumonia remains a non-trivial risk until excluded by chest imaging or other diagnostics.\n5. Statement evaluation: Claiming pneumonia is 'ruled out' contradicts risk principles - absence of key symptoms reduces likelihood but doesn't exclude this high-severity condition without confirmatory testing.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "33",
    "premise": "Patient presents with clinical features suggestive of meningitis. Currently hemodynamically stable, afebrile, and alert. No signs of raised intracranial pressure on examination. Lumbar puncture was attempted but unsuccessful. Discussed with Consultant Dr. A. Smith, who reviewed the case and, given the patient\u2019s stability and presumed viral etiology, advised deferring the procedure. Empirical antiviral therapy was initiated. No antibiotics started at this stage. Plan for lumbar puncture to be performed by senior consultant on 06/07/2025.",
    "statement": "Given the patient\u2019s stable condition, the consultant\u2019s decision to delay the lumbar puncture until the following day is safe.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. Extract candidates: Potential risks include bacterial meningitis (not definitively ruled out due to unsuccessful LP), delayed diagnosis, and progression to sepsis/neurologic complications. Viral meningitis (presumed) carries lower severity. 2. Likelihood: Bacterial meningitis likelihood is uncertain but not excluded (LP failed, no CSF data). Viral is presumed but unconfirmed. 3. Severity: Bacterial meningitis is life-threatening (high severity); viral meningitis typically moderate severity. 4. Risk comparison: Even a small likelihood of bacterial meningitis (high severity) outweighs the lower-risk viral scenario. Deferring LP delays definitive diagnosis and appropriate antibiotic therapy if bacterial. 5. Management implication: Safety requires either ruling out bacterial meningitis (not done) or mitigating risk (antibiotics not initiated). Consultant's decision leaves high-severity risk unaddressed. 6. Conclusion: The statement contradicts risk principles as a non-trivial risk of catastrophic harm persists.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract candidates: Potential risks include bacterial meningitis (not definitively ruled out due to unsuccessful LP), delayed diagnosis, and progression to sepsis/neurologic complications. Viral meningitis (presumed) carries lower severity. 2. Likelihood: Bacterial meningitis likelihood is uncertain but not excluded (LP failed, no CSF data). Viral is presumed but unconfirmed. 3. Severity: Bacterial meningitis is life-threatening (high severity); viral meningitis typically moderate severity. 4. Risk comparison: Even a small likelihood of bacterial meningitis (high severity) outweighs the lower-risk viral scenario. Deferring LP delays definitive diagnosis and appropriate antibiotic therapy if bacterial. 5. Management implication: Safety requires either ruling out bacterial meningitis (not done) or mitigating risk (antibiotics not initiated). Consultant's decision leaves high-severity risk unaddressed. 6. Conclusion: The statement contradicts risk principles as a non-trivial risk of catastrophic harm persists.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "34",
    "premise": "A 45-year-old man with a known shellfish allergy experienced an episode of anaphylaxis after dining at a restaurant. Shortly after eating, he developed breathing difficulty and collapsed. He was administered intramuscular epinephrine at the scene but lost consciousness. Witnesses reported tonic-clonic movements and urinary incontinence during the episode. He was taken to the emergency department, where he received intravenous adrenaline and supportive care.",
    "statement": "The patient should be referred to the First Seizure (FIT) clinic.",
    "label": "entailment",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. **Extract candidates**: Adverse events include anaphylaxis-induced hypoxia (A) and plausible latent diagnoses include primary seizure disorder (B). The tonic-clonic movements and urinary incontinence could represent a true seizure (B) or anoxic seizure secondary to anaphylaxis (A).\n2. **Likelihood**: Anoxic seizures due to hypoxia from anaphylaxis are more probable (directly linked to the event). However, primary seizure disorder remains plausible (no EEG/neuroimaging reported to rule it out).\n3. **Severity**: Undiagnosed epilepsy (B) carries high risk (future untreated seizures, injury, status epilepticus). Anoxic seizures (A) are transient but require addressing the underlying allergy.\n4. **Risk comparison**: While anaphylaxis is the immediate cause, failure to rule out a primary seizure disorder (B) poses a severe, irreversible risk if missed. The statement proposes referral to FIT clinic, which would evaluate for primary seizure.\n5. **Management implication**: Since severe hazard (B) is not ruled out (no neuro workup documented), referral is necessary to mitigate risk. Discharging without this step would leave a high-severity risk unaddressed.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. **Extract candidates**: Adverse events include anaphylaxis-induced hypoxia (A) and plausible latent diagnoses include primary seizure disorder (B). The tonic-clonic movements and urinary incontinence could represent a true seizure (B) or anoxic seizure secondary to anaphylaxis (A).\n2. **Likelihood**: Anoxic seizures due to hypoxia from anaphylaxis are more probable (directly linked to the event). However, primary seizure disorder remains plausible (no EEG/neuroimaging reported to rule it out).\n3. **Severity**: Undiagnosed epilepsy (B) carries high risk (future untreated seizures, injury, status epilepticus). Anoxic seizures (A) are transient but require addressing the underlying allergy.\n4. **Risk comparison**: While anaphylaxis is the immediate cause, failure to rule out a primary seizure disorder (B) poses a severe, irreversible risk if missed. The statement proposes referral to FIT clinic, which would evaluate for primary seizure.\n5. **Management implication**: Since severe hazard (B) is not ruled out (no neuro workup documented), referral is necessary to mitigate risk. Discharging without this step would leave a high-severity risk unaddressed.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "35",
    "premise": "Adverse Events: A 72-year-old patient receiving chemotherapy developed febrile neutropenia on Day 10 of Cycle 1. Temperature was 38.6\u00b0C, absolute neutrophil count (ANC) 0.2 x10\u2079/L. Managed as outpatient with oral antibiotics. No hospital admission or IV antibiotics were arranged. Patient monitored via phone follow-up.",
    "statement": "The adverse event was managed appropriately.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. Extract candidates: The adverse event is febrile neutropenia (ANC 0.2, fever 38.6\u00b0C). Potential latent risks include sepsis progression and inadequate infection control.\n2. Severity: Febrile neutropenia in chemotherapy patients carries high baseline risk (mortality 5-20% in high-risk cases). ANC <0.5 x10\u2079/L with fever meets high-risk criteria per IDSA guidelines.\n3. Likelihood: Outpatient oral antibiotic management contradicts standard recommendations for high-risk patients who typically need IV antibiotics and hospitalization. This increases likelihood of treatment failure.\n4. Risk comparison: Standard management reduces mortality by ensuring early intervention for occult infections. Outpatient care lacks capacity to monitor/treat rapid clinical changes (e.g., septic shock).\n5. Statement evaluation: Current management fails to mitigate catastrophic risks inherent to high-risk febrile neutropenia. Guidelines-based care would require hospitalization + IV antibiotics \u2192 statement contradicts evidence-based risk management.",
        "pred": "contradiction",
        "fact_verification": "incorrect",
        "reasoning_verification": "incorrect",
        "overall_verification": false
      },
      {
        "reasoning": "1. Extract candidates: Adverse event is febrile neutropenia (ANC 0.2 x10\u2079/L, fever 38.6\u00b0C). Plausible latent risks include sepsis progression and treatment failure due to inadequate infection control.\n2. Severity: Febrile neutropenia with ANC <0.5 x10\u2079/L meets IDSA high-risk criteria (supported by premise data). Life-threatening complications (e.g., septic shock) are possible if untreated.\n3. Likelihood: Outpatient oral antibiotic management contradicts IDSA guidelines for high-risk patients requiring IV antibiotics. Phone monitoring cannot detect rapid clinical deterioration.\n4. Risk comparison: Standard management (IV antibiotics + hospitalization) mitigates severe hazards by enabling early intervention. Outpatient care fails to address potential catastrophic decompensation (severe harm) despite being less likely than stable outcomes.\n5. Statement evaluation: Guidelines define appropriate management as IV antibiotics + hospitalization for high-risk cases. Current approach omits these \u2192 risk of severe unmanaged harm persists. Statement contradicts evidence-based standards.",
        "pred": "contradiction"
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract candidates: Adverse event is febrile neutropenia (ANC 0.2 x10\u2079/L, fever 38.6\u00b0C). Plausible latent risks include sepsis progression and treatment failure due to inadequate infection control.\n2. Severity: Febrile neutropenia with ANC <0.5 x10\u2079/L meets IDSA high-risk criteria (supported by premise data). Life-threatening complications (e.g., septic shock) are possible if untreated.\n3. Likelihood: Outpatient oral antibiotic management contradicts IDSA guidelines for high-risk patients requiring IV antibiotics. Phone monitoring cannot detect rapid clinical deterioration.\n4. Risk comparison: Standard management (IV antibiotics + hospitalization) mitigates severe hazards by enabling early intervention. Outpatient care fails to address potential catastrophic decompensation (severe harm) despite being less likely than stable outcomes.\n5. Statement evaluation: Guidelines define appropriate management as IV antibiotics + hospitalization for high-risk cases. Current approach omits these \u2192 risk of severe unmanaged harm persists. Statement contradicts evidence-based standards.",
      "pred": "contradiction"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "36",
    "premise": [
      "Adverse Events 1:",
      "  Total: 35/51 (68.63%)",
      "  Constipation 20/51 (39.22%)",
      "  Blood disorder 1/51 (1.96%)",
      "  Hypomagnesemia 1/51 (1.96%)",
      "  Platelets count decrease 1/51 (1.96%)",
      "  Thrombosis 6/51 (11.7%)",
      "  Vision-blurred vision 1/51 (1.96%)",
      "  Radiation oesophagitis 1/51 (1.96%)",
      "  Nausea 2/51 (3.92%)",
      "  Vomiting 2/51 (3.92%)",
      "  General symptom 2/51 (3.92%)",
      "  Headache 1/51 (1.96%)",
      "  Bone pain 1/51 (1.96%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of constipation.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 36: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:156"
      }
    ]
  },
  {
    "problem_id": "37",
    "premise": [
      "Adverse Events 2:",
      "  Total: 40/60 (66.67%)",
      "  Fatigue 25/60 (41.67%)",
      "  Anaphylaxis 3/60 (5.00%)",
      "  Injection site reaction 4/60 (6.67%)",
      "  Rash 2/60 (3.33%)",
      "  Headache 3/60 (5.00%)",
      "  Dizziness 2/60 (3.33%)",
      "  Mild hypotension 1/60 (1.67%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of fatigue.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 37: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:156"
      }
    ]
  },
  {
    "problem_id": "38",
    "premise": [
      "Adverse Events 3:",
      "  Total: 28/55 (50.91%)",
      "  Dry mouth 18/55 (32.73%)",
      "  Bradycardia 2/55 (3.64%)",
      "  Syncope 1/55 (1.82%)",
      "  Transient dizziness 3/55 (5.45%)",
      "  Injection site reaction 2/55 (3.64%)",
      "  Anxiety 1/55 (1.82%)",
      "  Fatigue 1/55 (1.82%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of dry mouth.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 38: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:156"
      }
    ]
  },
  {
    "problem_id": "39",
    "premise": [
      "Adverse Events 7:",
      "  Total: 50/70 (71.43%)",
      "  Injection site pain 20/70 (28.57%)",
      "  Myocardial infarction 3/70 (4.29%)",
      "  Hypertensive crisis 5/70 (7.14%)",
      "  Seizure 2/70 (2.86%)",
      "  Dizziness 3/70 (4.29%)",
      "  Nausea 2/70 (2.86%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of injection site pain.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 39: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:156"
      }
    ]
  },
  {
    "problem_id": "40",
    "premise": [
      "Adverse Events 8:",
      "  Total: 55/80 (68.75%)",
      "  Fatigue 25/80 (31.25%)",
      "  Anaphylaxis 3/80 (3.75%)",
      "  Respiratory distress 5/80 (6.25%)",
      "  Hypotension 4/80 (5.00%)",
      "  Diarrhea 4/80 (5.00%)",
      "  Rash 3/80 (3.75%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of fatigue.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 40: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:156"
      }
    ]
  }
]